Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration

Part of paid clinical trials in Indianapolis, Indiana.

Sponsor
Price Vision Group
Study ID
NCT03971357
Phase
PHASE2/PHASE3
Status
Terminated

Conditions

  • Fuchs' Endothelial Dystrophy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Netarsudil — DRUG
    netarsudil opthalmic solution 0.02%
  • Placebo — DRUG
    Placebo eye drops

Study Details

Subjects with Fuchs dystrophy will be randomized to use either netarsudil or placebo eye drops to determine if the use of netarsudil accelerates migration of host peripheral corneal endothelial cells to restore the central endothelial cell layer.

Key Dates

Start date
Jul 22, 2019
Status verified
Aug 2021
Primary completion
Aug 26, 2021
Completion
Aug 26, 2021

Study Design

Enrollment
19 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Netarsudil
    Netarsudil ophthalmic solution 0.02%, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner
  • Placebo Comparator: Placebo
    Placebo eye drop, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner.

Primary Outcome Measure

Corneal Clearing After Endothelial Removal for Treatment of Fuchs Dystrophy [ Time Frame: 5 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Price Vision GroupIndianapolisIndiana46260-

Find similar trials in Indianapolis, IN

By research site
Price Vision Group· Indianapolis, IN

Related Studies